Chemo Group has been a leader in the research, development and manufacture of pharmaceutical products for over 40 years. In November 2017, the Spanish multinational announced a name change to Insud Pharma, which integrates three pharma brands – Chemo, Exeltis and mAbxience. Chemo is the industrial division, developing and manufacturing APIs and finished dosage forms in key therapeutic areas. Exeltis has a strong portfolio of brand-name drugs in women’s health, dermatology, endocrinology, and CNS. And mAbxience is an international business specializing in R&D and manufacture of biosimilars. Present in over 40 countries worldwide, Insud Pharma employs over 6,000 people at 15 plants and 10 R&D Centers.